BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/18/2026 5:34:52 AM | Browse: 1 | Download: 0
 |
Received |
|
2026-08-10 08:04 |
 |
Peer-Review Started |
|
2026-08-10 08:04 |
 |
First Decision by Editorial Office Director |
|
|
 |
Return for Revision |
|
2026-09-20 03:16 |
 |
Revised |
|
2026-10-01 13:59 |
 |
Publication Fee Transferred |
|
|
 |
Editorial Processing by Scientific Editor |
|
2026-10-28 07:35 |
 |
Final Academic Decision by Editor-in-Chief |
|
|
 |
Publication Technical Verification by Editorial Office Director |
|
2026-10-28 10:27 |
 |
Articles in Press |
|
2026-10-28 10:27 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2026-11-10 09:24 |
 |
Publish the Manuscript Online |
|
2026-11-18 05:34 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Minireviews |
| Article Title |
Trial architecture in contemporary cardio-oncology: Why parallel-group randomized controlled trials may not fit every cardiotoxicity phenotype
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Radhia Chems Telli |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Radhia Chems Telli, Researcher, Department of Medicine, University of Biskra, B.P. 145, RP, Biskra 07000, Algeria. radhia.telli@univ-biskra.dz |
| Key Words |
Cardio-oncology; Cardiotoxicity; Cardioprotection; Clinical trial design; Adaptive clinical trials; Biomarker-enriched trial design; Master protocols; Registry-based randomized trial; Immune checkpoint inhibitor myocarditis; Cancer therapy-related cardiovascular toxicity |
| Core Tip |
This minireview is concerned with how cardioprotection trials are designed, not with the pharmacological efficacy of any particular cardioprotective agent. These trials have relied almost exclusively on the conventional parallel-group randomized controlled trial, regardless of which cardiotoxicity phenotype is studied. This minireview maps six contemporary phenotypes – from anthracycline-related left ventricular dysfunction to radiation-induced cardiovascular disease – against established trial-design principles (biomarker-enriched, adaptive, master-protocol, and registry-embedded designs) already used elsewhere in medicine. Only anthracycline-related left ventricular dysfunction is currently supported by conducted trials using an alternative architecture; the remaining five phenotypes require prospective evaluation of untested conceptual directions. |
| Publish Date |
2026-11-18 05:34 |
| Citation |
Telli RC. Trial architecture in contemporary cardio-oncology: Why parallel-group randomized controlled trials may not fit every cardiotoxicity phenotype. World J Cardiol 2026; 18(11): 126635
|
| URL |
https://www.wjgnet.com/1949-8462/full/v18/i11/126635.htm |
| DOI |
https://doi.org/10.4330/wjc.126635 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.